A putative placebo analysis of the effects of LCZ696 on clinical outcomes in heart failure

AIMS: Although active-controlled trials with renin–angiotensin inhibitors are ethically mandated in heart failure with reduced ejection fraction, clinicians and regulators often want to know how the experimental therapy would perform compared with placebo. The angiotensin receptor-neprilysin inhibit...

Descripción completa

Detalles Bibliográficos
Autores principales: McMurray, John, Packer, Milton, Desai, Akshay, Gong, Jianjian, Greenlaw, Nicola, Lefkowitz, Martin, Rizkala, Adel, Shi, Victor, Rouleau, Jean, Solomon, Scott, Swedberg, Karl, Zile, Michael R., Andersen, Karl, Arango, Juan Luis, Arnold, Malcolm, Be˘lohlávek, Jan, Böhm, Michael, Boytsov, Sergey, Burgess, Lesley, Cabrera, Walter, Chen, Chen-Huan, Erglis, Andrejs, Fu, Michael, Gomez, Efrain, Gonzalez, Angel, Hagege, Albert-Alain, Katova, Tzvetana, Kiatchoosakun, Songsak, Kim, Kee-Sik, Bayram, Edmundo, Martinez, Felipe, Merkely, Bela, Mendoza, Iván, Mosterd, Arend, Negrusz-Kawecka, Marta, Peuhkurinen, Keijo, Ramires, Felix, Refsgaard, Jens, Senni, Michele, Sibulo, Antonio S., Silva-Cardoso, José, Squire, Iain, Starling, Randall C., Vinereanu, Dragos, Teerlink, John R., Wong, Raymond
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2015
Materias:
FASTTrack Clinical Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4328198/
https://www.ncbi.nlm.nih.gov/pubmed/25416329
http://dx.doi.org/10.1093/eurheartj/ehu455

Ejemplares similares

Ejemplares similares